Keyword: Monsanto

Bayer CEO Werner Baumann admitted the company isn't doing enough to keep up with U.S. consumers' rapid shift toward buying health products online.

Bayer's Monsanto deal hasn't even closed yet, and healthcare sales are already showing cause for concern.

Bayer's consumer health ambitions have been frustrated by declining U.S. sales, and now it's shaking up management to get the unit back on track.

Bayer's third-quarter results are sparking more concern about its Monsanto buy.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer now, its future pharma growth could be in jeopardy.

People with diabetes are waiting too long to discuss vision problems with their doctors, according to a new study funded by Bayer.

Some of Bayer's Big Pharma rivals would lash themselves to a mast during a storm to post sales growth as high as 7%. But that's just what Bayer did, with Q3 numbers that could "confirm investor fears" about the fallout from its Monsanto megamerger.

If Bayer's proposed $66 billion purchase of Monsanto goes through, Bayer is considering dropping the Monsanto name.

Critics of Bayer’s $66 billion Monsanto deal have said it would hurt the German drugmaker’s pharma ambitions. Bayer itself, though, isn’t worried about that.